title: Effect of bevacizumab on strabismus surgery in rabbits.
abstract: OBJECTIVE
  This study was conducted to evaluate the effect of bevacizumab on postoperative inflammation and adhesion after strabismus surgery in rabbits.
  
  
  METHODS
  Fifteen New Zealand White rabbits were used for this study. Both eyes of each of 15 rabbits underwent reinsertion of the superior rectus muscle (SRM). The right eye of each animal received a subconjunctival bevacizumab injection (2.5 mg/0.1 mL). As controls, normal saline was injected subconjunctivally in the contralateral eye. To assess acute inflammation changes, macrophages, neutrophils, and monocytes were localized in the SRM using an anti-CD11b antibody at postoperative day 1. At 4 weeks, the sites of muscle reattachment were evaluated grossly for postoperative adhesion score and histologically for collagen formation.
  
  
  RESULTS
  Infiltration of acute inflammatory cells showing CD11b+ was significantly reduced in the bevacizumab injection group (P=0.001). The difference in adhesion (SRM/conjunctiva and SRM/sclera) scores between the two groups was statistically insignificant (P=0.93 and P=0.85). Histopathologic findings revealed that muscle changes and fibrosis showed no significant difference (P=0.69) between the treated eyes and the control eyes.
  
  
  CONCLUSIONS
  The intraoperative use of bevacizumab reduced inflammatory cell infiltration in the early stage of the procedure, but it was insufficient to prevent postoperative adhesion in rabbit eyes after extraocular muscle surgery.
authors.affiliation: Department of Ophthalmology, Pusan National University Hospital, Medical Research Institute, Pusan National University, Busan, Korea.
authors.forename: Hee Young
authors.initials: HY
authors.lastname: Choi
authors.forename: Jung Hoon
authors.initials: JH
authors.lastname: Lee
authors.forename: Ji Eun
authors.initials: JE
authors.lastname: Lee
authors.forename: Jae Ho
authors.initials: JH
authors.lastname: Jung
mesh_terms: D000210:Acute-Phase Reaction / Q000188:drug therapy / Q000517:prevention & control; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D039481:CD11b Antigen / Q000378:metabolism; D003228:Conjunctiva; D005355:Fibrosis / Q000188:drug therapy / Q000517:prevention & control; D007249:Inflammation / Q000188:drug therapy* / Q000517:prevention & control; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D009801:Oculomotor Muscles / Q000601:surgery; D011183:Postoperative Complications / Q000188:drug therapy* / Q000517:prevention & control; D011817:Rabbits; D013285:Strabismus / Q000601:surgery*; D000267:Tissue Adhesions / Q000188:drug therapy / Q000517:prevention & control
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D039481:CD11b Antigen; D000068258:Bevacizumab